118 related articles for article (PubMed ID: 24394199)
41. IL2RA is associated with persistence of rheumatoid arthritis.
van Steenbergen HW; van Nies JA; Ruyssen-Witrand A; Huizinga TW; Cantagrel A; Berenbaum F; van der Helm-van Mil AH
Arthritis Res Ther; 2015 Sep; 17(1):244. PubMed ID: 26350950
[TBL] [Abstract][Full Text] [Related]
42. Association of the ABCB1 C3435T polymorphism with responsiveness to and toxicity of DMARDs in rheumatoid arthritis : A meta-analysis.
Lee YH; Bae SC; Song GG
Z Rheumatol; 2016 Sep; 75(7):707-15. PubMed ID: 26184955
[TBL] [Abstract][Full Text] [Related]
43. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
Korpela M; Laasonen L; Hannonen P; Kautiainen H; Leirisalo-Repo M; Hakala M; Paimela L; Blåfield H; Puolakka K; Möttönen T;
Arthritis Rheum; 2004 Jul; 50(7):2072-81. PubMed ID: 15248204
[TBL] [Abstract][Full Text] [Related]
44. Expression of methotrexate transporters and metabolizing enzymes in rheumatoid synovial tissue.
Stamp LK; Hazlett J; Highton J; Hessian PA
J Rheumatol; 2013 Sep; 40(9):1519-22. PubMed ID: 23858048
[TBL] [Abstract][Full Text] [Related]
45. Polymorphisms in ATP-binding cassette transporter genes and interaction with diet and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study.
Kopp TI; Andersen V; Tjonneland A; Vogel U
Scand J Gastroenterol; 2015; 50(12):1469-81. PubMed ID: 26109419
[TBL] [Abstract][Full Text] [Related]
46. [Tailor-made medicine and genomic drug discovery in rheumatoid arthritis].
Taniguchi A; Kamatani N
Nihon Rinsho; 2005 Jan; 63 Suppl 1():686-90. PubMed ID: 15799443
[No Abstract] [Full Text] [Related]
47. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
[TBL] [Abstract][Full Text] [Related]
48. [Association between AIF-1 gene polymorphisms and response to rheumatoid arthritis treatment with sulphasalazine].
Dabrowska-Zamojcin E; Herczyńska MM; Pawlik A
Ann Acad Med Stetin; 2013; 59(2):39-42. PubMed ID: 25026748
[TBL] [Abstract][Full Text] [Related]
49. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
[TBL] [Abstract][Full Text] [Related]
50. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
51. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
[TBL] [Abstract][Full Text] [Related]
52. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database.
Edwards CJ; Arden NK; Fisher D; Saperia JC; Reading I; Van Staa TP; Cooper C
Rheumatology (Oxford); 2005 Nov; 44(11):1394-8. PubMed ID: 16030083
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
[TBL] [Abstract][Full Text] [Related]
54. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
[TBL] [Abstract][Full Text] [Related]
55. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
Kooloos WM; Wessels JA; van der Straaten T; Allaart CF; Huizinga TW; Guchelaar HJ
Pharmacogenomics; 2010 Feb; 11(2):163-75. PubMed ID: 20136356
[TBL] [Abstract][Full Text] [Related]
56. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
[TBL] [Abstract][Full Text] [Related]
57. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
[TBL] [Abstract][Full Text] [Related]
58. Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.
Kuuliala A; Leirisalo-Repo M; Möttönen T; Hannonen P; Nissilä M; Kautiainen H; Korpela M; Julkunen H; Hakola M; Repo H;
Clin Exp Rheumatol; 2005; 23(2):243-6. PubMed ID: 15895898
[TBL] [Abstract][Full Text] [Related]
59. Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis.
Proudman SM; Cleland LG; Metcalf RG; Sullivan TR; Spargo LD; James MJ
Br J Nutr; 2015 Sep; 114(6):885-90. PubMed ID: 26283657
[TBL] [Abstract][Full Text] [Related]
60. Methotrexate pharmacogenetics in rheumatoid arthritis.
Brinker RR; Ranganathan P
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S33-9. PubMed ID: 21044431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
